Recent Advances in Genetic Technologies

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts trends across genetic technologies enabling enhanced insights across disease pathogenesis and management. The corresponding clinical validation scenario is depicted along with the industry interactions. A summary of active and completed clinical studies for VM202, a novel gene therapy candidate for ALS, is also presented.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the lates

Table of Contents

Recent Advances in Genetic TechnologiesInnovations in Genetic TechnologiesUS Scientists Leverage CRISPR to Edit Genes in Human EmbryosGene Therapy Candidate for Amyotrophic Lateral Sclerosis Reports Favorable Results in Phase 1/2 StudiesDecoding the Genetics of Bipolar and Major Depressive DisordersAdvancing Gene Therapy Research through Collaborative EffortsClinical Trial Analysis and Industry InteractionsSummary of Active and Completed Clinical Studies for VM202Summary of Key Contacts

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.